The Food and Drug Administration (FDA) yesterday said that another batch of AstraZeneca’s lipid-lowering drug Crestor was found to have been adulterated with counterfeit drugs, so the company has agreed to initiate a recall for all batches on the market.
The administration last weekend confirmed that batch number MV503 of Crestor 10mg film-coated tablets contained counterfeit drugs in similar packaging, and all the medication from that batch was recalled from hospitals and pharmacies.
“The agency received the report about the counterfeit drugs on Thursday last week and immediately launched an investigation; examinations confirmed that there were counterfeit drugs being sold,” administration Director-General Shou-Mei Wu (吳秀梅) said yesterday.
Photo: courtesy of the Taichung Health Bureau
The New Taipei District Prosecutors’ Office took two suspects into custody over the weekend, and they may face up to 10 years in prison or a fine up to NT$100 million (US$3.24 million) for producing counterfeit drugs under the Pharmaceutical Affairs Act (藥事法).
Another consignment of Crestor 10mg film-coated tablets, batch number MK479, was also found to contain counterfeit drugs, so the FDA said it asked AstraZeneca to recall all batches of the product in the interests of public safety.
“The main ingredient that has been added to the counterfeit drugs is actually another type of lipid-lowering drug, atorvastatin, that used to be commonly prescribed, so people who have taken the counterfeit drugs need not worry too much,” Wu said, adding that people should consult doctors or pharmacists if they have any questions.
According to National Health Insurance (NHI) Administration statistics, more than 200,000 boxes of Crestor are prescribed each month in Taiwan by NHI physicians, administration official Chih Lan-hui (遲蘭慧) said.
AstraZeneca told the administration that it has a sufficient quantity of the medication in stock to replace the recalled products, so patients would not be forced to take other types of drugs, she said.
Asked to respond to media reports that two other types of oral lipid-lowering drugs and one type of oral hypoglycemic drugs had been adulterated with counterfeit drugs and marketed under other brand names, the administration said it did not have any information on the issue, but that prosecutors and the administration would investigate.
Eight Chinese naval vessels and 24 military aircraft were detected crossing the median line of the Taiwan Strait between 6am yesterday and 6am today, the Ministry of National Defense said this morning. The aircraft entered Taiwan’s northern, central, southwestern and eastern air defense identification zones, the ministry said. The armed forces responded with mission aircraft, naval vessels and shore-based missile systems to closely monitor the situation, it added. Eight naval vessels, one official ship and 36 aircraft sorties were spotted in total, the ministry said.
The Ministry of Foreign Affairs (MOFA) today said that if South Korea does not reply appropriately to its request to correct Taiwan’s name on its e-Arrival card system before March 31, it would take corresponding measures to alter how South Korea is labeled on the online Taiwan Arrival Card system. South Korea’s e-Arrival card system lists Taiwan as “China (Taiwan)” in the “point of departure” and “next destination” fields. The ministry said that it changed the nationality for South Koreans on Taiwan’s Alien Resident Certificates from “Korea” to “South Korea” on March 1, in a gesture of goodwill and based on the
Taiwanese officials were shown the first of 66 F-16V fighter jets purchased by Taiwan from the United States, the Ministry of National Defense said yesterday, adding the aircraft has completed an initial flight test and is expected to be delivered later this year. A delegation led by Deputy Minister of National Defense Hsu Szu-chien (徐斯儉) visited Lockheed Martin’s F-16 C/D Block 70 (also known as F-16V) assembly line in South Carolina on March 16 to view the aircraft. The jet will undergo a final acceptance flight in the US before being delivered to Taiwan, the
The New Taipei Metro's Sanyin Line and the eastern extension of the Taipei Metro's Tamsui-Xinyi Line (Red Line) are scheduled to begin operations in June, the National Development Council said today. The Red Line, which terminates at Xiangshan Station, would be connected by the 1.4km extension to a new eastern terminal, Guangci/Fengtian Temple Station, while the Sanyin Line would link New Taipei City's Tucheng and Yingge stations via Sanxia District (三峽). The council gave the updates at a council meeting reviewing progress on public construction projects for this year. Taiwan's annual public infrastructure budget would remain at NT$800 billion (US$25.08 billion), with NT$97.3
RSS